149 related articles for article (PubMed ID: 22959905)
1. Effect of subcutaneous depot-medroxyprogesterone acetate (DMPA-SC) on serum androgen markers in normal-weight, obese, and extremely obese women.
Segall-Gutierrez P; Du J; Niu C; Ge M; Tilley I; Mizraji K; Stanczyk FZ
Contraception; 2012 Dec; 86(6):739-45. PubMed ID: 22959905
[TBL] [Abstract][Full Text] [Related]
2. Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously.
Segall-Gutierrez P; Taylor D; Liu X; Stanzcyk F; Azen S; Mishell DR
Contraception; 2010 Jun; 81(6):487-95. PubMed ID: 20472115
[TBL] [Abstract][Full Text] [Related]
3. Deterioration in cardiometabolic risk markers in obese women during depot medroxyprogesterone acetate use.
Segall-Gutierrez P; Xiang AH; Watanabe RM; Trigo E; Stanczyk FZ; Liu X; Jurow R; Buchanan TA
Contraception; 2012 Jan; 85(1):36-41. PubMed ID: 22067800
[TBL] [Abstract][Full Text] [Related]
4. A pilot study examining short-term changes in bone mineral density among class 3 obese users of depot-medroxyprogesterone acetate.
Segall-Gutierrez P; Agarwal R; Ge M; Lopez C; Hernandez G; Stanczyk FZ
Eur J Contracept Reprod Health Care; 2013 Jun; 18(3):199-205. PubMed ID: 23530919
[TBL] [Abstract][Full Text] [Related]
5. Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: I. Endocrine effects.
Zimmerman Y; Foidart JM; Pintiaux A; Minon JM; Fauser BC; Cobey K; Coelingh Bennink HJ
Contraception; 2015 Feb; 91(2):127-33. PubMed ID: 25604900
[TBL] [Abstract][Full Text] [Related]
6. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males.
Vermeulen A; Kaufman JM; Giagulli VA
J Clin Endocrinol Metab; 1996 May; 81(5):1821-6. PubMed ID: 8626841
[TBL] [Abstract][Full Text] [Related]
7. Effect of oral versus transdermal steroidal contraceptives on androgenic markers.
White T; Jain JK; Stanczyk FZ
Am J Obstet Gynecol; 2005 Jun; 192(6):2055-9. PubMed ID: 15970897
[TBL] [Abstract][Full Text] [Related]
8. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
9. Contraceptive efficacy and safety of DMPA-SC.
Jain J; Jakimiuk AJ; Bode FR; Ross D; Kaunitz AM
Contraception; 2004 Oct; 70(4):269-75. PubMed ID: 15451329
[TBL] [Abstract][Full Text] [Related]
10. Novel dehydroepiandrosterone troche supplementation improves the serum androgen profile of women undergoing in vitro fertilization.
Keane KN; Hinchliffe PM; Namdar N; Conceicao JL; Newsholme P; Yovich JL
Drug Des Devel Ther; 2015; 9():5569-78. PubMed ID: 26487801
[TBL] [Abstract][Full Text] [Related]
11. Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive.
Pantoja M; Medeiros T; Baccarin MC; Morais SS; Bahamondes L; Fernandes AM
Contraception; 2010 Feb; 81(2):107-11. PubMed ID: 20103446
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of the decreased androgen levels in obese men.
Giagulli VA; Kaufman JM; Vermeulen A
J Clin Endocrinol Metab; 1994 Oct; 79(4):997-1000. PubMed ID: 7962311
[TBL] [Abstract][Full Text] [Related]
13. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
Stomati M; Monteleone P; Casarosa E; Quirici B; Puccetti S; Bernardi F; Genazzani AD; Rovati L; Luisi M; Genazzani AR
Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974
[TBL] [Abstract][Full Text] [Related]
14. Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL.
Westhoff C; Jain JK; Milsom I; Ray A
Contraception; 2007 Apr; 75(4):261-7. PubMed ID: 17362703
[TBL] [Abstract][Full Text] [Related]
15. Androgen and SHBG serum concentrations in late post-menopause women.
Skałba P; Wójtowicz M; Sikora J
Med Sci Monit; 2003 Mar; 9(3):CR152-6. PubMed ID: 12640346
[TBL] [Abstract][Full Text] [Related]
16. Oral, transdermal and vaginal combined contraceptives induce an increase in markers of chronic inflammation and impair insulin sensitivity in young healthy normal-weight women: a randomized study.
Piltonen T; Puurunen J; Hedberg P; Ruokonen A; Mutt SJ; Herzig KH; Nissinen A; Morin-Papunen L; Tapanainen JS
Hum Reprod; 2012 Oct; 27(10):3046-56. PubMed ID: 22811306
[TBL] [Abstract][Full Text] [Related]
17. A cross-sectional study of the forearm bone mineral density in long-term current users of the injectable contraceptive depot medroxyprogesterone acetate.
Viola AS; Castro S; Bahamondes MV; Fernandes A; Viola CF; Bahamondes L
Contraception; 2011 Nov; 84(5):e31-7. PubMed ID: 22018135
[TBL] [Abstract][Full Text] [Related]
18. Androgen levels in women using a single implant of nomegestrol acetate.
Barbosa I; Coutinho E; Athayde C; Ladipo OA; Olsson SE; Ulmsten U
Contraception; 1996 Jan; 53(1):37-40. PubMed ID: 8631188
[TBL] [Abstract][Full Text] [Related]
19. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene.
Christodoulakos G; Lambrinoudaki I; Panoulis C; Sioulas V; Rizos D; Caramalis G; Botsis D; Creatsas G
Maturitas; 2005 Apr; 50(4):321-30. PubMed ID: 15780533
[TBL] [Abstract][Full Text] [Related]
20. Androgens in relationship to cardiovascular risk factors in the menopausal transition.
Mesch VR; Siseles NO; Maidana PN; Boero LE; Sayegh F; Prada M; Royer M; Schreier L; Benencia HJ; Berg GA
Climacteric; 2008; 11(6):509-17. PubMed ID: 18991078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
